Discovery of novel type II c-Met inhibitors based on BMS-777607

• Twenty-two analogs based on BMS-777607 were designed and synthesized.
• Two analogs were more potent than BMS-777607 in vitro studies.
• Novel designed scaffolds may provide a new basis for further optimization.

Twenty-two new analogs based on the structure of BMS-777607 were designed, synthesized, and evaluated to determine their biological activities. Compounds bearing a cyclic sulfonamide or α-chloropiperidone scaffold exhibited good activity, which may provide a new basis for further structural optimization. Quinoline-containing analogs exhibited better results than did their counterparts with an aminopyrimidine, aminopyridine, or pyrrolopyridine unit. Two analogs, 22d and 22e, stood out as the most potent c-Met inhibitors with IC50s of 0.9 and 1.7 nM, respectively. These two compounds were more potent than BMS-777607 in enzymatic inhibition and cell proliferation studies.

Twenty-two new analogs based on the structure of BMS-777607 were designed, synthesized, and evaluated to determine their biological activities. Two compounds were more potent than BMS-777607 in enzymatic inhibition and cell proliferation studies.Figure optionsDownload as PowerPoint slide